Rate of early treatment discontinuation among a community sample of naive hepatitis C patients on Rebetron combination therapy.

被引：0
|
作者：
Belville-Robertson, TL
Brown, KA
Moonka, DK
Mahr, G
Clemensen, LR
Mankato, N
Lucas, MB
Eshelman, AK
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] ISJ Clin Northridge, N Mankato, MN USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1716
引用
收藏
页码：601A / 601A
页数：1
相关论文
共 50 条
  • [31] Viral kinetics of the hepatitis C virus in patients treated with high dose daily combination therapy.
    Bekkerinq, FC
    Brouwer, JT
    Niesters, HGM
    Siebelink, CHJ
    Schalm, SW
    HEPATOLOGY, 1998, 28 (04) : 288A - 288A
  • [32] Combination therapy with daily interferon alpha and ribavirin in naive patients with chronic hepatitis C.
    Rothstein, KD
    Suvannasankha, A
    Digreggorio, K
    Gross, F
    Peikin, S
    Mushnick, A
    Deangelo, C
    Salowe, D
    Siegel, H
    Shaw, E
    Bond, K
    Manzarbeitia, C
    HEPATOLOGY, 1999, 30 (04) : 619A - 619A
  • [33] Work productivity among treatment-naive patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment
    Aggarwal, J.
    Vera-Llonch, M.
    Donepudi, M.
    Suthoff, E.
    Younossi, Z.
    Goss, T. F.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 (01) : 8 - 17
  • [34] Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs
    Treloar, Carla
    Hull, Peter
    Bryant, Joanne
    Hopwood, Max
    Grebely, Jason
    Lavis, Yvonna
    DRUG AND ALCOHOL DEPENDENCE, 2011, 116 (1-3) : 52 - 56
  • [35] An evaluation demonstrating continued efficacy and improved safety and tolerability in 17 patients switched to PEGASYS® after discontinuation from REBETRON™ for the treatment of chronic hepatitis C
    Perrillo, RP
    Rothstein, KD
    Alam, I
    Thuluvath, PJ
    Palmer, M
    Pockros, PJ
    Pappas, SC
    Doerschuk, BS
    Cantwell, S
    JOURNAL OF HEPATOLOGY, 2001, 34 : 146 - 146
  • [36] Treatment of hepatitis C with daily induction dose interferon alpha 2b plus ribavirin followed by daily combination therapy in patients who are treatment naive or have previously failed an interferon based therapy.
    Lawitz, EJ
    Kadakia, SC
    Cantu, N
    Nader, P
    Cox, J
    Ganeshappa, KP
    Reddy, G
    Nguyen, TT
    Diamond, K
    Lindner, M
    Ostower, V
    Vemura, R
    GASTROENTEROLOGY, 2000, 118 (04) : A1462 - A1462
  • [37] Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients
    Gish, R
    Arora, S
    Nelson, D
    Fernandez, H
    Lamon, K
    JOURNAL OF HEPATOLOGY, 2004, 40 : 141 - 142
  • [38] Effectiveness of Interferon α-2b and Ribavirin Combination Therapy in the Treatment of Naive Chronic Hepatitis C Patients in Clinical Practice
    Shehab, Thomas M.
    Fontana, Robert J.
    Oberhelman, Kelly
    Marrero, Jorge A.
    Su, Grace L.
    Lok, Anna S. F.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (05) : 425 - 431
  • [39] EFFICACY OF PEGINTERFERON ALPHA-2A AND RIBAVIRIN COMBINATION THERAPY IN TREATMENT-NAIVE ESTONIAN PATIENTS WITH CHRONIC HEPATITIS C
    Brjalin, Vadim
    Salupere, Riina
    Tallo, Tatjana
    Kuznetsova, Tatiana
    Priimaegi, Ljudmilla
    Tefanova, Valentina
    CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2012, 20 (02) : 150 - 155
  • [40] High dose induction therapy with consensus interferon followed by combination therapy with ribavirin for treatment-naive patients with chronic hepatitis C.
    Kaiser, S
    Kreysel, C
    Gregor, M
    HEPATOLOGY, 2000, 32 (04) : 561A - 561A
12345